ArticleCase reports in oncological medicine2025
Pancytopenia With Subsequent Diagnosis of Hemophagocytic Lymphohistiocytosis in a Middle-Aged Male.
Article in Case reports in oncological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome resulting from uncontrolled activation of the immune system. It is characterized by persistent fever, cytopenias, organomegaly, and a constellation of laboratory abnormalities including hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia, and elevated soluble interleukin-2 receptor levels. HLH can be broadly classified into primary (familial) and secondary forms, the latter often triggered by infections, malignancies, autoimmune diseases, or other systemic insults. Despite advancements in diagnostic criteria and therapeutic strategies, HLH continues to carry high morbidity and mortality, largely due to its nonspecific and variable presentation that often leads to delays in diagnosis. Early recognition and prompt initiation of immunosuppressive therapy are crucial to improving outcomes. We are presenting a case of symptomatically gastrointestinal-dominant HLH presentation potentially due to an unusual trigger of TMP/SMX in an otherwise healthy adult male who presented with flu-like symptoms accompanied with abdominal pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.